C07C251/30

NITRONE COMPOUNDS AND THEIR USE IN PERSONAL CARE
20170190655 · 2017-07-06 ·

Provided are compounds and compositions thereof that are useful as antioxidants in personal care formulations. The compounds are of the Formula I:

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are independently H, OH, C.sub.1-C.sub.6 alkoxy, COOH, COO.sup.M.sup.+ or O.sup.31 M.sup.+ where M.sup.+ is a sodium, potassium, or ammonium ion, wherein at least two of R.sup.1, R.sup.2, R.sup.3, R.sup.4, or R.sup.5 are OH, and R.sup.6, R.sup.7, R.sup.8, R.sup.9, and R.sup.10, are independently H, OH, C.sub.1-C.sub.6 alkoxy, COOH, COO.sup.M.sup.+ or O.sup.31 M.sup.+ where M.sup.+ is a sodium, potassium, or ammonium ion, or a substituent of Formula II:

##STR00002##

wherein R.sup.11, R.sup.12, R.sup.13, R.sup.14,and R.sup.15are independently H, OH, C.sub.1-C.sub.6 alkoxy, COOH, COO.sup.M.sup.+ or O.sup.31 M.sup.+ where M.sup.+ is a sodium, potassium, or ammonium ion, provided that one of R.sup.6, R.sup.7, R.sup.8, R.sup.9, and R.sup.10 is a substituent of Formula II.

NITRONE COMPOUNDS AND THEIR USE IN PERSONAL CARE
20170190655 · 2017-07-06 ·

Provided are compounds and compositions thereof that are useful as antioxidants in personal care formulations. The compounds are of the Formula I:

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are independently H, OH, C.sub.1-C.sub.6 alkoxy, COOH, COO.sup.M.sup.+ or O.sup.31 M.sup.+ where M.sup.+ is a sodium, potassium, or ammonium ion, wherein at least two of R.sup.1, R.sup.2, R.sup.3, R.sup.4, or R.sup.5 are OH, and R.sup.6, R.sup.7, R.sup.8, R.sup.9, and R.sup.10, are independently H, OH, C.sub.1-C.sub.6 alkoxy, COOH, COO.sup.M.sup.+ or O.sup.31 M.sup.+ where M.sup.+ is a sodium, potassium, or ammonium ion, or a substituent of Formula II:

##STR00002##

wherein R.sup.11, R.sup.12, R.sup.13, R.sup.14,and R.sup.15are independently H, OH, C.sub.1-C.sub.6 alkoxy, COOH, COO.sup.M.sup.+ or O.sup.31 M.sup.+ where M.sup.+ is a sodium, potassium, or ammonium ion, provided that one of R.sup.6, R.sup.7, R.sup.8, R.sup.9, and R.sup.10 is a substituent of Formula II.

NITRONE COMPOUNDS AND THEIR USE IN PERSONAL CARE
20170079896 · 2017-03-23 ·

Provided are compounds and compositions thereof that are useful as antioxidants in personal care formulations. The compounds are of the Formula I:

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are independently H, OH, C.sub.1-C.sub.6 alkoxy, COOH, COO.sup.M.sup.+ or O.sup.M.sup.+, where M.sup.+ is a sodium, potassium, or ammonium ion, and R.sup.6, R.sup.7, R.sup.8, R.sup.9, and R.sup.10, are independently H, OH, C.sub.1-C.sub.6 alkoxy, COOH, COO.sup.M.sup.+ or O.sup.M.sup.+, where M.sup.+ is a sodium, potassium, or ammonium ion, or a substituent of Formula II:

##STR00002##

wherein R.sup.11, R.sup.12, R.sup.13, R.sup.14, and R.sup.15 are independently H, OH, C.sub.1-C.sub.6 alkoxy, COOH, COO.sup.M.sup.+ or O.sup.M.sup.+, where M.sup.+ is a sodium, potassium, or ammonium ion, provided that one of R.sup.6, R.sup.7, R.sup.8, R.sup.9, and R.sup.10 is a substituent of Formula II.

N-(4-(bis(4-(dimethylamino)phenyl)methylene)-8-(dimethylamino)
09567291 · 2017-02-14 · ·

This disclosure relates to N-(4-(bis(4-(dimethylamino)phenyl)methylene)-8 -(dimethylamino)naphthalen-1(4H)-ylidene)-N-methylmethanaminium, derivatives, and uses related thereto. In certain embodiments, the disclosure relates to compounds of formula I. In certain embodiments, the disclosure relates to methods of treating or preventing Nox related diseases and conditions comprising administering an effective amount of compounds disclosed herein to a subject in need thereof. In certain embodiments, the Nox related disease or condition is cancer.

N-(4-(bis(4-(dimethylamino)phenyl)methylene)-8-(dimethylamino)
09567291 · 2017-02-14 · ·

This disclosure relates to N-(4-(bis(4-(dimethylamino)phenyl)methylene)-8 -(dimethylamino)naphthalen-1(4H)-ylidene)-N-methylmethanaminium, derivatives, and uses related thereto. In certain embodiments, the disclosure relates to compounds of formula I. In certain embodiments, the disclosure relates to methods of treating or preventing Nox related diseases and conditions comprising administering an effective amount of compounds disclosed herein to a subject in need thereof. In certain embodiments, the Nox related disease or condition is cancer.

Tedizolid intermediate and efficient preparation method thereof

The efficient preparation method of a tedizolid intermediate includes the following steps: 1) subjecting 2-fluoro-4-substituted phenylacetic acid to a reaction with a Vilsmeier reagent, and adding a resulting reaction solution to an MX aqueous solution for quenching to obtain an intermediate shown in formula (II); and 2) subjecting the intermediate shown in formula (II) obtained in step 1) and 1-(2-methyl-2H-tetrazol-5-yl)ethanone to one-pot synthesis in the presence of an alkali and an ammonia source to obtain the intermediate shown in formula (I). In this method, a pyridine ring of the key intermediate shown in formula (I) is obtained through a ring-closing reaction of the 1-(2-methyl-2H-tetrazol-5-yl)ethanone and a Vinamidinium salt, and a key methyltetrazolyl group is introduced into the structure, which successfully avoids the use of highly-toxic sodium cyanide and sodium azide, the use of expensive palladium catalyst, and the use of methylation with low selectivity.

Tedizolid intermediate and efficient preparation method thereof

The efficient preparation method of a tedizolid intermediate includes the following steps: 1) subjecting 2-fluoro-4-substituted phenylacetic acid to a reaction with a Vilsmeier reagent, and adding a resulting reaction solution to an MX aqueous solution for quenching to obtain an intermediate shown in formula (II); and 2) subjecting the intermediate shown in formula (II) obtained in step 1) and 1-(2-methyl-2H-tetrazol-5-yl)ethanone to one-pot synthesis in the presence of an alkali and an ammonia source to obtain the intermediate shown in formula (I). In this method, a pyridine ring of the key intermediate shown in formula (I) is obtained through a ring-closing reaction of the 1-(2-methyl-2H-tetrazol-5-yl)ethanone and a Vinamidinium salt, and a key methyltetrazolyl group is introduced into the structure, which successfully avoids the use of highly-toxic sodium cyanide and sodium azide, the use of expensive palladium catalyst, and the use of methylation with low selectivity.

Pigmented and fluorescent compounds derived from the addition of a primary or secondary amine to an aldehyde

The invention provides a compound of formula (I): wherein R1, R2, and R3 have any of the values described in the specification, as well as compositions comprising a compound of formula (I), methods for preparing compounds of formula (I), and methods for detecting the presence of an amine in a sample. The compounds are useful as pigments.

Pigmented and fluorescent compounds derived from the addition of a primary or secondary amine to an aldehyde

The invention provides a compound of formula (I): wherein R1, R2, and R3 have any of the values described in the specification, as well as compositions comprising a compound of formula (I), methods for preparing compounds of formula (I), and methods for detecting the presence of an amine in a sample. The compounds are useful as pigments.